Faecal microbiota transplantation (FMT) has recently re-emerged as a viable therapeutic option for colonic disorders. Its efficacy has been proved in the treatment of Clostridium difficile infection which has encouraged research into the use of FMT for other disorders involving gut dysbiosis, such as ulcerative colitis (UC), a chronic inflammatory disease characterized by relapsing and remitting colonic inflammation. Although the FMT protocol for C. difficile treatment is well established, there are numerous additional factors to consider when applying FMT to treat inflammatory diseases. Various studies have attempted to address these factors but technical inconsistency between reports has resulted in a failure to achieve clinically significant findings. Case reports of FMT in UC have shown favorable outcomes yet demonstrating these effects on a larger scale has proved difficult. The following review aims to explore these issues and to analyze why they may be hindering the progression of FMT therapy in UC.

Citations

Citations to this article as recorded by  

• The Role of Fecal Microbiota Transplantation in the Induction of Remission in Ulcerative Colitis
  Adam Saleh, Shyon Parsa, Manuel Garza, Eamonn M.M. Quigley, Bincy P. Abraham
  Digestive Diseases.2023; 41(4): 656.     CrossRef
• Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches
  Jana Štofilová, Monika Kvaková, Anna Kamlárová, Emília Hijová, Izabela Bertková, Zuzana Guľašová
  Biomedicines.2022; 10(9): 2236.     CrossRef
• Finding intestinal fortitude: Integrating the microbiome into a holistic view of depression mechanisms, treatment, and resilience
  M.C. Flux, Christopher A. Lowry
  Neurobiology of Disease.2020; 135: 104578.     CrossRef
• In Situ Profiling of the Three Dominant Phyla Within the Human Gut Using TaqMan PCR for Pre-Hospital Diagnosis of Gut Dysbiosis
  Young Jae Jo, Setu Bazie Tagele, Huy Quang Pham, YeonGyun Jung, Jerald Conrad Ibal, SeungDae Choi, Gi-Ung Kang, Sowon Park, Yunkoo Kang, Seung Kim, Hong Koh, Jae-Ho Shin
  International Journal of Molecular Sciences.2020; 21(6): 1916.     CrossRef
• Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment
  Xiao Yan Guo, Xin Juan Liu, Jian Yu Hao
  Journal of Digestive Diseases.2020; 21(3): 147.     CrossRef
• Potential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability
  Stephanie A. Flowers, Shubha Bhat, James C. Lee
  Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2020; 40(7): 704.     CrossRef
• Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis: a real world intention-to-treat analysis
  Ajit Sood, Ramit Mahajan, Garima Juyal, Vandana Midha, Charanpreet Singh Grewal, Varun Mehta, Arshdeep Singh, Mohan C Joshi, Vikram Narang, Kirandeep Kaur, Hasrat Sidhu
  Intestinal Research.2019; 17(1): 78.     CrossRef
• Multi-session fecal microbiota transplantation using colonoscopy has favorable outcomes for the treatment of steroid-dependent ulcerative colitis
  Young-Seok Cho
  Intestinal Research.2019; 17(1): 6.     CrossRef
• Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis
  Xiao Ding, Qianqian Li, Pan Li, Ting Zhang, Bota Cui, Guozhong Ji, Xiang Lu, Faming Zhang
  Drug Safety.2019; 42(7): 869.     CrossRef

Citations

Citations to this article as recorded by  

• Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response
  Alex Adams, Vipin Gupta, Waled Mohsen, Thomas P Chapman, Deloshaan Subhaharan, Pradeep Kakkadasam Ramaswamy, Sudheer Kumar, Saurabh Kedia, Colleen GC McGregor, Tim Ambrose, Bruce D George, Rebecca Palmer, Oliver Brain, Alissa Walsh, Vineet Ahuja, Simon P
  Gut.2023; 72(3): 433.     CrossRef
• Inflammatory bowel disease
  Mayank Jain, Jayanthi Venkataraman
  Indian Journal of Medical Research.2021; 153(4): 421.     CrossRef
• High Serum Osmolality May Predict the Disease Severity in Patients with Acute Ulcerative Colitis
  Abdussamed VURAL, Aslı VURAL, Selahattin VURAL, Selim TURFAN, Ahmet Cumhur DÜLGER
  Online Türk Sağlık Bilimleri Dergisi.2020; 5(2): 324.     CrossRef

• Relationship Between Vitamin D Deficiency and Disease Activity in Patients with Inflammatory Bowel Disease in Ahvaz, Iran

  
  Esmat Rasouli, Narges Sadeghi, Abazar Parsi, Seyed Jalal Hashemi, Morteza Nayebi, Aliakbar Shayesteh
  Clinical and Experimental Gastroenterology.2020; Volume 13: 419.     CrossRef
• A current overview of corticosteroid use in active ulcerative colitis
  Marco Salice, Fernando Rizzello, Carlo Calabrese, Lucia Calandrini, Paolo Gionchetti
  Expert Review of Gastroenterology & Hepatology.2019; 13(6): 557.     CrossRef
• Optimal management of acute severe ulcerative colitis
  Saransh Jain, Vineet Ahuja, Jimmy K Limdi
  Postgraduate Medical Journal.2019; 95(1119): 32.     CrossRef
• A challenge in diagnosis and management of ulcerative colitis in elderly patient with atypical presentation: A reported case
  Panutchaya Kongon, Vorapatu Tangsirapat, Vittawat Ohmpornuwat, Kannakrit Sumtong, Vichack Chakrapan Na Ayudhya, Kobkool Chakrapan Na Ayudhya, Paiboon Sookpotarom, Paisarn Vejchapipat
  International Journal of Surgery Case Reports.2019; 61: 234.     CrossRef

Proton pump inhibitors (PPIs) are widely used though an association with hypomagnesaemia and hypocalcaemia has only been described since 2006. Patients typically present after years of stable dosing with musculoskeletal, neurological or cardiac arrhythmic symptoms, but it is likely that many cases are under-recognised. Magnesium levels resolve rapidly on discontinuation of PPI therapy and hypomagnesaemia recurs rapidly on rechallenge with any agent in the class. The cellular mechanisms of magnesium homeostasis are increasingly being understood, including both passive paracellular absorption through claudins and active transcellular transporters, including the transient receptor potential channels (TRPM6) identified in the intestine and nephron. PPIs may alter luminal pH by modulating pancreatic secretions, affecting non-gastric H+K+ATPase secretion, altering transporter transcription or channel function. A small reduction in intestinal absorption appears pivotal in causing cumulative deficiency. Risk factors have been associated to help identify patients at risk of this effect but clinical vigilance remains necessary for diagnosis.

Citations

Citations to this article as recorded by  

• Use of Acid-Suppression Therapy and Odds of Migraine and Severe Headache in the National Health and Nutrition Examination Survey
  Margaret Slavin, Cara L. Frankenfeld, Alexander B. Guirguis, Elizabeth K. Seng
  Neurology Clinical Practice.2024;[Epub]     CrossRef
• Magnesium Homeostasis
  Aubrey R. Morrison
  Clinical Journal of the American Society of Nephrology.2023; 18(7): 969.     CrossRef
• Risk of urinary stone formation associated to proton pump inhibitors: A systematic review and metanalysis
  Rawa Bapir, Kamran Hassan Bhatti, Ahmed Eliwa, Herney Andrés García-Perdomo, Nazim Gherabi, Derek Hennessey, Vittorio Magri, Panagiotis Mourmouris, Adama Ouattara, Gianpaolo Perletti, Joseph Philipraj, Konstantinos Stamatiou, Musliu Adetola Tolani, Lazaro
  Archivio Italiano di Urologia e Andrologia.2022; 94(4): 507.     CrossRef
• An overview of diagnosis and management of drug‐induced hypomagnesemia
  George Liamis, Ewout J. Hoorn, Matilda Florentin, Haralampos Milionis
  Pharmacology Research & Perspectives.2021;[Epub]     CrossRef
• Effects of Proton Pump Inhibitors on the Gastrointestinal Microbiota in Gastroesophageal Reflux Disease
  Yi-Chao Shi, Shun-Tian Cai, Ya-Ping Tian, Hui-Jun Zhao, Yan-Bing Zhang, Jing Chen, Rong-Rong Ren, Xi Luo, Li-Hua Peng, Gang Sun, Yun-Sheng Yang
  Genomics, Proteomics & Bioinformatics.2019; 17(1): 52.     CrossRef
• Atrial fibrillation and gastrooesophageal reflux disease: association mechanisms, treatment approaches
  O. N. Antropova, N. V. Pyrikova, I. V. Osipova
  Russian Journal of Cardiology.2019; (7): 103.     CrossRef
• Do stop me now: gastric acid-reducing drugs following renal transplantation
  Ines Held, Rhodri Pyart
  Journal of Kidney Care.2018; 3(1): 6.     CrossRef
• Magnesium homeostasis in cattle: absorption and excretion
  Holger Martens, Sabine Leonhard-Marek, Monika Röntgen, Friederike Stumpff
  Nutrition Research Reviews.2018; 31(1): 114.     CrossRef
• A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors
  Li-Yuan Yu, Lu-Ning Sun, Xue-Hui Zhang, Yue-Qi Li, Lei Yu, Zi-Qing-Yun Yuan, Ling Meng, Hong-Wen Zhang, Yong-Qing Wang
  Advances in Therapy.2017; 34(5): 1070.     CrossRef
• Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis
  Young Joo Yang, Chang Seok Bang, Gwang Ho Baik, Tae Young Park, Suk Pyo Shin, Ki Tae Suk, Dong Joon Kim
  BMC Gastroenterology.2017;[Epub]     CrossRef
• Proton Pump Inhibitors Should be Used with Caution in Critically Ill Patients to Prevent the Risk of Clostridium difficile Infection
  Jung Hwa Min, You Sun Kim
  Gut and Liver.2016; 10(4): 493.     CrossRef
• Impact of Long-Term Proton Pump Inhibitor Therapy on Gut Microbiota in F344 Rats: Pilot Study
  Cheol Min Shin, Nayoung Kim, Yong Sung Kim, Ryoung Hee Nam, Ji Hyun Park, Dong Ho Lee, Yeong-Jae Seok, Yeon-Ran Kim, Joo-Hyon Kim, Jung Min Kim, Joo Sung Kim, Hyun Chae Jung
  Gut and Liver.2016; 10(6): 896.     CrossRef